abstract |
The present invention relates to compounds capable of modulating the activity and / or expression of protein kinases SCYL1, ADCK1 and GRK5, thereby increasing insulin expression and / or release. The invention further relates to a method for identifying said compounds for treating carbohydrate metabolic disorders. The invention further relates to a method for treating carbohydrate metabolic disorders, particularly type 2 diabetes mellitus. |